ºÒÀÀ¼º ¿ëÇ÷¼º ºóÇ÷À» Áö´Ñ ¼Ò¾Æ Àü½ÅÈ«¹Ý·çǪ½º¿¡¼­ÀÇ Rituximab Ä¡·á 1·Ê
Delayed and Long-term Remission of Refractory Hemolytic Anemia in a Child with Systemic Lupus Erythematosus Treated with Rituximab

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸÁö 2014³â 21±Ç 4È£ p.196 ~ p.200

¹ÚÁÖȯ(Park Ju-Hwan) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
ÀÓÀç¿í(Im Jae-Uk) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
ÀüÈ«±æ(Jun Hong-Gil) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
¹ÚÇý¹Î(Park Hye-Min) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
Ãֽ¿ø(Choi Seung-Won) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
¹Ú»ó±Ô(Park Sang-Kyu) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ¼Ò¾Æ°úÇб³½Ç
¿ÀÁö¼±(Oh Ji-Seon) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¿ï»ê´ëÇб³º´¿ø ³»°úÇб³½Ç

Abstract

Autoimmune hemolytic anemia (AIHA) is a relatively com-mon cause of anemia in children and adults with systemic lupus erythematosus (SLE). Although AIHA responds to steroids, in case of refractory or steroid-dependent AIHA, immunosuppressants and intravenous immunoglobulin have been used as second line agents. Rituximab, an anti-CD20 monoclonal antibody, is emerging in the treatment of SLE refractory to conventional therapy. Herein, we report a case of delayed and sustained remission of refractory hemolytic anemia in a child with SLE, post rituximab treatment. A 12-year-old female child with dizziness was referred to our department and was diagnosed with SLE combined with he-molytic anemia and renal tubular acidosis. Since frequent relapse of hemolytic anemia had occurred during the ste-roid tapering course, even though she had been treated with additional immunosuppressants (azathioprine, mycopheno-late mofetil), the patient received 2 doses of rituximab 500 mg at 2 weeks interval at 18 months post diagnosis. After 15 months of rituximab administration, her anemia and re-nal tubular acidosis were fully recovered, enough to stop all medications. She remained well without recurrence for up to 3 years and 4 months after rituximab treatment.

Å°¿öµå

Systemic lupus erythematosus, Hemolytic ane-mia, Rituximab, Steroid
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå